NUTRIOSE dietary fiber supplementation improves insulin resistance and determinants of metabolic syndrome in overweight men: a double-blind, randomized, placebo-controlled study

2010 ◽  
Vol 35 (6) ◽  
pp. 773-782 ◽  
Author(s):  
Shuguang Li ◽  
Laetitia Guerin-Deremaux ◽  
Marine Pochat ◽  
Daniel Wils ◽  
Cheryl Reifer ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Metabolic Syndrome ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Test Group ◽  
Lipoprotein Cholesterol ◽  
Controlled Study ◽  
Low Density ◽  
Low Density Lipoprotein Cholesterol ◽  
Double Blind

The influence of dietary fiber on determinants of metabolic syndrome is controversial. The objective of this study was to determine the effects of NUTRIOSE supplementation on insulin resistance and the determinants of metabolic syndrome in overweight men. In this double-blind, randomized, placebo-controlled study, we supplemented the diets of overweight Chinese men with 250 mL of fruit juice that contained NUTRIOSE (Test group: n = 60, age = 30.4 ± 4.3 years, body mass index (BMI) = 24.5 ± 0.2 kg·m–2) or a maltodextrin placebo (Control group: n = 60, age = 31.6 ± 4.1 years, BMI = 24.5 ± 0.3 kg·m–2) at a dosage of 17 g twice daily for 12 weeks. Daily caloric intake, body composition, blood chemistry, and blood pressure were evaluated every 4 weeks during the trial. Test subjects consumed fewer calories per day and had greater reductions in body weight, BMI, body fat percentage, and waist circumference than Control subjects. All markers of glucose metabolism improved in the Test group, with increases in adiponectin and reductions in glucose, insulin, homeostasis model assessment-estimated insulin resistance, glycosylated hemoglobin, and glycated albumin (all p < 0.01). Similarly, all lipid measures improved with increases in high-density lipoprotein cholesterol and reductions in total cholesterol, low-density lipoprotein cholesterol, very low-density lipoprotein cholesterol, and triglycerides (all p < 0.01). No changes were observed in systolic blood pressure between groups. Most components of glucose metabolism and the lipid profile were significantly better in the Test than in the Control subjects. No adverse events or gastrointestinal complaints were reported in either group. Supplementation with NUTRIOSE for 12 weeks is well tolerated, lowers insulin resistance, and improves determinants of metabolic syndrome in overweight men.

scholarly journals Relationship between C-reactive protein and features of the metabolic syndrome in military pilots in the Serbia and Montenegro

2005 ◽  
Vol 62 (11) ◽  
pp. 811-819
Author(s):  
Aleksandra Jovelic ◽  
Goran Radjen ◽  
Stojan Jovelic ◽  
Marica Markovic
Keyword(s):  
Metabolic Syndrome ◽  
High Density Lipoprotein ◽  
High Density Lipoprotein Cholesterol ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Lipoprotein Cholesterol ◽  
Low Density ◽  
C Reactive Protein ◽  
Low Density Lipoprotein Cholesterol ◽  
Reactive Protein

Background/Aim. C-reactive protein is an independent predictor of the risk of cardiovascular events and diabetes mellitus in apparently healthy men. The relationship between C-reactive protein and the features of metabolic syndrome has not been fully elucidated. To assess the cross-sectional relationship between C-reactive protein and the features of metabolic syndrome in healthy people. Methods. We studied 161 military pilots (agee, 40?6 years) free of cardiovascular disease, diabetes mellitus and active inflammation on their regular annual medical control. Age, total cholesterol, low density lipoprotein cholesterol, high density lipoprotein cholesterol, triglycerides, fasting glucose, glycosylated hemoglobin, blood pressure, smoking habit, waist circumference and body mass index were evaluated. Plasma C-reactive protein was measured by the immunonephelometry (Dade Behring) method. Metabolic syndrome was defined according to the National Cholesterol Education Program Expert Panel. Results. The mean C-reactive protein concentrations in the subjects grouped according to the presence of 0, 1, 2 and 3 or more features of the metabolic syndrome were 1.11, 1.89, 1.72 and 2.22 mg/L, respectively (p = 0.023) with a statistically, significant difference between those with 3, and without metabolic syndrome (p = 0.01). In the simple regression analyses C-reactive protein did not correlate with the total cholesterol, low density lipoprotein cholesterol, high density lipoprotein cholesterol, body mass index and blood pressure (p > 0.05). In the multiple regression analysis, waist circumference (? = 0.411, p = 0.000), triglycerides to high density lipoprotein cholesterol ratio (? = 0.774, p = 0.000), smoking habit (? = 0.236, p = 0.003) and triglycerides (? = 0.471, p = 0.027) were independent predictors of C-reactive protein. Conclusions. Our results suggested a cross-sectional independent correlation between the examined cardiovascular risk factors as the predominant features of metabolic syndrome and C-reactive protein in the group of apparently healthy subjects. The lack of correlation of C-reactive protein with the total cholesterol and low density lipoprotein cholesterol in our study may suggest their different role in the process of atherosclerosis and the possibility to determine C-reactive protein in order to identify high-risk subjects not identified with cholesterol screening.

scholarly journals Association of the Apolipoprotein B/Apolipoprotein A-I Ratio, Metabolic Syndrome Components, Total Cholesterol, and Low-Density Lipoprotein Cholesterol with Insulin Resistance in the Population of Georgia

2014 ◽  
Vol 2014 ◽  
pp. 1-8 ◽  
Author(s):  
Zaza Makaridze ◽  
Elene Giorgadze ◽  
Ketevan Asatiani
Keyword(s):  
Metabolic Syndrome ◽  
Apolipoprotein B ◽  
Regression Models ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Lipoprotein Cholesterol ◽  
Low Density ◽  
Low Density Lipoprotein Cholesterol ◽  
Apolipoprotein A ◽  
Multiple Regression Models

The study was designed to assess the association between insulin resistance (IR) and apolipoprotein B/apolipoprotein A-I ratio (ApoB/ApoA-I ratio), metabolic syndrome (MetS) components, total cholesterol (TC), and low-density lipoprotein cholesterol (LDL-C) in the nondiabetic population of Georgia. The subjects were 1522 Georgians of Caucasian origin (mean age = 45 years, 653 women) without diabetes who had visited the clinics for a related health checkup between 2012 and 2013. IR was calculated using the computer homeostasis model assessment (HOMA2-IR) and was defined as the upper quartile. MetS was diagnosed using the updated ATP-III definition of the metabolic syndrome. Logistic and multiple regression models were used to estimate the association between IR and other components. IR was positively correlated with age, ApoB, ApoB/ApoA-I ratio, MetS components (excluding high-density lipoprotein cholesterol—HDL-C), LDL-C, fasting insulin, and TC and negatively correlated with HDL-C and ApoA-I in both sexes (allP<0.001). In the logistic regression models, gender, age, ApoB/ApoA-I ratio, diastolic pressure, HDL-C, LDL-C, fasting glucose, and triglycerides were the covariates significantly associated with IR (OR: 8.64, 1.03, 17.95, 1.06, 0.13, 1.17, 3.75, and 2.29, resp.; allP<0.05). Multiple regression models demonstrated that these components (except for HDL-C) made an independent contribution to the prediction of HOMA2 (allP<0.05).

scholarly journals To Compare the Effects of Terminalia Arjuna with Rosuvastatin on Total Cholesterol and Low Density Lipoprotein Cholesterol

2016 ◽  
Vol 5 (1) ◽  
pp. 1056
Author(s):  
Ved Prakash ◽  
Vijay kumar Sehgal ◽  
Vijay Kumar Bajaj ◽  
Harcharan Singh
Keyword(s):  
Total Cholesterol ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Lipoprotein Cholesterol ◽  
Controlled Study ◽  
Terminalia Arjuna ◽  
Low Density ◽  
Low Density Lipoprotein Cholesterol ◽  
Group I ◽  
The Difference

<strong>Background:</strong>In India, CVD is a leading cause of death. Among the modifiable risk factors, hyperlipidemia is one of the important factors. Therefore lowering cholesterol level is a key factor in controlling this disease.<p><strong>Objectives:</strong> To compare the effect of Terminalia arjuna, an indigenous drug with Rosuvastatin on serum total cholesterol and low density lipoprotein cholesterol levels, in patients of either sex with dyslipidemia.</p><p><strong>Material and Methods:</strong> An open prospective randomized controlled study was conducted in on 60 patients for the duration of 12 weeks. Patients were distributed into two groups of 30 patients each. Group I was given Rosuvastatin 10 mg daily and group II was given capsules containing bark powder of T.arjuna 500 mg twice daily. Patients TC and LDL-C levels were performed at baseline and then repeated at 4 weeks, 8 weeks and 12 weeks. The results of both the therapies were then compared and statistically analyzed.</p><p><strong>Results:</strong> T.arjuna leads to greater reduction in mean TC level than Rosuvastatin (-14.06±8.07% vs -10.10±5.39%), (- 24.73±10.69% vs -19.42±9.98%) and (-27.89±9.25% vs - 24.74±10.02%) at 4, 8 and 12 weeks respectively. The difference between both the groups was statistically non-significant (p&gt;0.05) at 4, 8 and 12 weeks. The reduction in mean LDL-C level was also greater with T.arjuna as compared to Rosuvastatin.</p><p><strong>Conclusion:</strong> Both Rosuvastatin and T.arjuna were effective in causing significant decrease in serum TC and LDLC levels, but T.arjuna had a slight edge over Rosuvastatin as it showed greater reduction in TC and LDL-C levels as compare to Rosuvastatin. And was found to be safe and well tolerated.</p>

Sign in / Sign up

Export Citation Format

Share Document